Biocon Limited

Rock Creek Pharmaceuticals, Inc.

Bicon Limited

Anthem Biosciences Pvt Ltd

Philip Morris Products S.a.

Tom Thomas Puthiaparampil

Jonnie R Williams

Sambasivam Ganesh

Madhavan Sridharan

Sumithra Srinath

Joy Mathew

Muppala S Raju

Thomas Kanathkunn David

Ganesh Sambasivam

Acharya Poornaprajna

Chandrashekar Aswathanarayanappa

Shanmughasamy Rajamahendra

Chandrashekhar Aswathanarayanappa

Ravindra Chandrappa Koramangala

Padudevastana Sathya Shanker

Rajulu Gavara Govinda

Thomas Kanathkunn Davis

Muppala Sarveswara Raju

Synthesis of the novel compound 3 (3-(5-substituted Oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester) to make Pyrroloquinoline quinone (PQQ) and using it for pharmaceutical purposes is described. More specifically, this disclosure relates to synthesizing the PQQ in an efficient method by using a novel intermediate Formula 1 resulting in a shorter process and higher yield of PQQ. A unique process to make sodium compound of PQQ using either sodium hydroxide and/or sodium carbonate is also shown.

Compounds of 3-(5-substituted Oxy-2, 4-dinitrophenyl)-2-oxo-propionic acid ester, synthesis and applications thereof

Anatabine citrate and formulations containing anatabine citrate are useful for promoting health and well-being.

Pharmaceutical, dietary supplement, and food grade salts of anatabine

Anatabine is obtained by reacting benzophenoneimine with 3-aminomethyl pyridine to form benzylhydrylidene-pyridin-3-yl-methyl-amine. The benzylhydrylidene-pyridin-3-yl-methyl-amine is treated with a non-nucleophilic base and a dielectrophile, such as cis-1,4-dichloro-2-butene, followed by acidification, then basification, to provide anatabine. The resulting anatabine is substantially free from contaminants and displays good stability. In an alternative embodiment, the benzylhydrylidene-pyridin-3-yl-methyl-amine may be used in the synthesis of other alkaloids such as anabasine, nornicotine, N-methylanabasine, and anabaseine.

Methods of synthesizing anatabine

In one aspect, the present invention provides a novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate, a key intermediate for the preparation of HMG-CoA reductase inhibitor.

Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate

In one aspect, the invention provides a process for the production of 5-(4-Fluoro-phenyl)-2-isopropyl-4-phenyl-1-(3,5,7-trihydroxy-heptyl)-1H-pyrrole-3-carboxylic acid phenylamide hemicalcium salt, stereoisomers thereof or polymorphs thereof from a (6-{2-[2-(4-Fluoro-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrolidin-1-yl]-ethyl}-2-phenyl-[1,3,2]dioxaborinan-4-yl)-acetic acid tert-butyl ester.

Process for the production of atorvastatin calcium

The present invention relates to a novel crystalline form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing the same.

Form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine

The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin rosuvastatin, pitavastatin, and fluvastatin.

Boronate esters

The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and fluvastatin.

In one aspect, the invention provides a process for the preparation of compounds of Formula I  

Process for stereoselective reduction of &#x3b2;-ketoesters

In one aspect, the invention provides a process for the preparation of a compound of Formula I  wherein G is alkyl or aryl, by employing a novel halo-substituted active methylene compound of Formula III  wherein X is halogen, and process of preparation thereof.

Growing community of inventors

Karnataka, India

Tom Thomas Puthiaparampil